1Systematic Review2021
Rendell MS · Expert Opin Investig Drugs (2021)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
14 peer-reviewed studies
What the evidence says
Most ARA-290 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2012–2021 with a typical study size of 9 participants.
Based on 14 studies · 5 RCTs · 9 total participants
Confidence
Moderate confidenceBy outcome
Only 1 study in the last 5 years
Rendell MS · Expert Opin Investig Drugs (2021)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A · Mol Med (2012)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Cerit H, Veer IM, Dahan A, Niesters M, Harmer CJ, Miskowiak KW · Eur Neuropsychopharmacol (2015)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ · Invest Ophthalmol Vis Sci (2017)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O · Mol Med (2013)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: Subjects receiving ARA 290 exhibited an improvement in hemoglobin A1c and lipid profiles... Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group.
Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, et al. · Mol Med (2015)
In plain English: In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms, as well as quality of life... In both populations, ARA290 lacked significant adverse effects.
Dahan A, Brines M, Niesters M, Cerami A, van Velzen M. · Pain Rep (2016)
In plain English: There was no improvement in mean change baseline-week 12 in BCVA, CRT, central retinal sensitivity or tear production... The cibinetide 12-week course was safe.
Lois N, Gardner E, McFarland M, Armstrong D, McNally C, Lavery NJ, et al. · J Clin Med (2020)
In plain English: ARA 290 treatment was consistently associated with a significant improvement of neuropathic pain symptoms in sarcoidosis patients... Given the excellent safety profile while reducing neuropathy symptoms, the prospects of ARA 290 treatment in sarcoid neuropathy seem promising.
van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A. · Expert Opin Investig Drugs (2014)
In plain English: CNF area is a useful variable for quantifying change in CNF morphology... in patients with SFN following cibinetide administration, an agent which promotes nerve repair.
Brines M, Culver DA, Ferdousi M, Tannemaat MR, van Velzen M, Dahan A, et al. · Sci Rep (2018)
In plain English: Activation of the IRR might provide benefit for diabetic wound healing.
Bitto A, Irrera N, Pizzino G, Pallio G, Mannino F, Vaccaro M, et al. · Biochim Biophys Acta Mol Basis Dis (2018)
In plain English: ARA 290 was able to specifically inhibit TRPV1 channel activity, and relieve the mechanical hypersensitivity induced by capsaicin.
Zhang W, Yu G, Zhang M. · Peptides (2016)
In plain English: Cibinetide activation of the IRR exerts potent anti-inflammatory effects, especially within the myeloid population, reduces disease activity and mortality in mice.
Nairz M, Haschka D, Dichtl S, Sonnweber T, Schroll A, Asshoff M, et al. · Sci Rep (2017)
In plain English: ARA 290 could effectively suppress EAN by attenuating inflammation and exerting direct cell protection... haematopoiesis was not induced by ARA 290 during EAN treatment.
Liu Y, Luo B, Han F, Li X, Xiong J, Jiang M, et al. · PLoS One (2014)